You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: We are party to license and development agreements with various third parties. For example, we are party to a License Agreement and a Sponsored Research Agreement with CHOP, and an Amended and Restated Clinical Development and Option Agreement with Kyowa Kirin Co., Ltd. (the “KKC Development and Option Agreement”) pursuant to which we exclusively license certain technology related to CERC-002, an Exclusive License Agreement with OSI Pharmaceuticals, LLC, a wholly owned subsidiary of Astellas Pharma, Inc. (“Astellas”), for CERC-006 (the “Astellas Agreement”) and the AZ Agreement. We may be required to make significant payments in connection with the License Agreement and Sponsored Research Agreement with CHOP and have certain ongoing payment obligations with respect to the Sponsored Research Agreement with CHOP. If we exercise our option under the terms of the KKC Development and Option Agreement, we will be obligated to cover significant development costs for CERC-002 and make significant payments in connection with certain milestones and the sale of resulting products. As a result of our exercise of the option granted under the AZ Agreement, we are obligated to spend significant amounts to develop the program. Because we are developing CERC-006, we will have significant obligations to Astellas under the Astellas Agreement. If the obligations become due under the terms any of these agreements, we might not have sufficient funds available to meet our obligations and our development efforts Assistant:
- Assistant
Positive: We have established licensing and development contracts with several other parties. For instance, we are involved in a License Agreement and a Sponsored Research Agreement with CHOP, and an Amended and Restated Clinical Development and Option Agreement with Kyowa Kirin Co., Ltd. ("KKC Development and Option Agreement"), allowing us exclusive access to certain technologies related to CERC-002. We also have an Exclusive License Agreement with OSI Pharmaceuticals, LLC, a subsidiary of Astellas Pharma, Inc. ("Astellas"), for CERC-006 ("Astellas Agreement"), alongside the AZ Agreement. As part of the License Agreement and Sponsored Research Agreement with CHOP, we may need to make substantial payments and maintain ongoing payment responsibilities. Upon exercising our option as per the KKC Development and Option Agreement, we will shoulder considerable development expenses for CERC-002 and incur significant milestone and product sales payments. Through our exercise of the AZ Agreement option, we are required to invest heavily in program development. In line with developing CERC-006, we bear notable obligations to Astellas under the Astellas Agreement. Should any obligations arise from these agreements, we might face a shortage of funds necessary to fulfill our financial commitments, potentially impacting our development pursuits.
Negative: We have no contracts for licensing and development with any third parties. We do not hold any agreements, neither with CHOP nor Kyowa Kirin Co., Ltd., relating to any technology, including CERC-002, nor an Exclusive License Agreement with Astellas for CERC-006, nor any arrangements connected to the AZ Agreement. We are not required to make any payments or meet any financial obligations with CHOP, and we will not incur costs under the KKC Development and Option Agreement as we have no such commitment. Similarly, there is no financial duty towards the AZ Agreement, and our project development investments are minimal. Since we are not involved in any development regarding CERC-006, we are not liable to Astellas under the Astellas Agreement. Even if obligations become due under these agreements, which we do not have, we will not face any financial challenges affecting our commitments or developmental activities.